Industry Experience
Novartis PhD Fellow
See Multistate and Joint Models for details about my 2 years of collaboration (Jan. 2021 through May 2022, then Spring 2025) with Novartis statisticians to model the efficacy of a cutting edge blood cancer immunotherapy using multistate and joint models.
Featured Work
- A. Prasadan, D. A. James, and J. Greenhouse. Assessing CAR-T immunotherapy outcomes using multistate models, pharmacokinetics, and tumor burden. Novartis Technical Report, 2022.
- Invited Topics Contributed Session, Joint Statistical Meetings (JSM), Toronto, 2023. Joint modeling of transduced cellular kinetics, tumor size, and survival endpoints.
Statistician at UPMC
At the Karikari Laboratory headed by Dr. Thomas K. Karikari, clinicians are studying the use of biomarkers in the blood as diagnostic tools for Alzheimer’s Disease (AD). These biomarkers offer a more cost-effective and less invasive way to evaluate large populations for AD. While existing studies tend to sample from economically privileged populations, this study followed a socioeconomically disadvantaged cohort to broaden our understanding of the disease. I was one of a few statisticians helping design and implement statistical methods to explore this rich clinical data. I worked at the lab from 2024 through Summer 2025.
Featured Work
- M. T. Dresse, P. C. L. Ferreira, A. Prasadan, J. L. Diaz, X. Zeng, B. Bellaver, G. Povala, V. L. Villemagne, M. I. Kamboh, A. D. Cohen, T. A. Pascoal, M. Ganguli, B. E. Snitz, C. E. Shaaban, T. K. Karikari. Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort, 2025. To appear in Alzheimer’s Research & Therapy.
Data Science Intern at Highmark Health
In the summer of 2022, I implemented a bi-level linear programming algorithm recently developed by a CMU PhD. The goal is to devise a health insurance network that can optimize patient utility while simultaneously minimizing costs.